Verastem Inc
Research Verastem Inc (VSTM) on Bullrun: market cap USD 640.61M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerVSTM
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 640.61M
- Financial periodQ2 2026
- RevenueUSD 40.08M
- Net income-USD 34.67M
- Free cash flow-USD 43.91M
- Gross margin89.9%
Valuation Snapshot
latest market cap is USD 640.61M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 30.91M | -USD 209.47M | -USD 147.13M | 82.9% | -3.02 | USD 204.99M | USD 87.17M | USD 57.20M |
| FY2024 | USD 10.00M | -USD 130.64M | -USD 104.80M | n/a | -3.66 | USD 88.82M | USD 40.72M | -USD 28.89M |
| FY2023 | n/a | -USD 87.37M | n/a | n/a | -3.96 | USD 77.91M | USD 40.09M | USD 57.37M |
| FY2022 | USD 2.60M | -USD 73.81M | n/a | n/a | -4.57 | USD 74.93M | USD 24.53M | USD 47.39M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 640.61M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 600.15M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 231.54M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 205.68M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 80.04M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 379.84M | n/a | n/a | n/a |
About Verastem Inc
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Verastem Inc's market cap?
Verastem Inc's market capitalization is USD 640.61M.
What does Verastem Inc do?
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.